BR112021017620A2 - Compostos macrocíclicos - Google Patents
Compostos macrocíclicosInfo
- Publication number
- BR112021017620A2 BR112021017620A2 BR112021017620A BR112021017620A BR112021017620A2 BR 112021017620 A2 BR112021017620 A2 BR 112021017620A2 BR 112021017620 A BR112021017620 A BR 112021017620A BR 112021017620 A BR112021017620 A BR 112021017620A BR 112021017620 A2 BR112021017620 A2 BR 112021017620A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- macrocyclic compounds
- macrocyclic
- carboxyindole
- mcl
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical group C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
compostos macrocíclicos. são revelados compostos macrocíclicos da fórmula (i) que compreendem um anel de 2-carboxi-indol. tais compostos, e seus sais farmaceuticamente aceitáveis, são úteis como inibidores de mcl-1 (leucemia de células mieloides-1). os compostos podem ser usados no tratamento de uma doença ou condição, como câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815508P | 2019-03-08 | 2019-03-08 | |
| PCT/US2020/021516 WO2020185606A1 (en) | 2019-03-08 | 2020-03-06 | Macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017620A2 true BR112021017620A2 (pt) | 2021-11-09 |
Family
ID=72426452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017620A BR112021017620A2 (pt) | 2019-03-08 | 2020-03-06 | Compostos macrocíclicos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144854A1 (pt) |
| EP (1) | EP3924358A4 (pt) |
| JP (1) | JP2022524191A (pt) |
| KR (1) | KR20210153051A (pt) |
| CN (1) | CN113950481A (pt) |
| AU (1) | AU2020238002A1 (pt) |
| BR (1) | BR112021017620A2 (pt) |
| CA (1) | CA3131939A1 (pt) |
| IL (1) | IL286102A (pt) |
| MX (1) | MX2021010321A (pt) |
| SG (1) | SG11202109367WA (pt) |
| TW (1) | TW202100533A (pt) |
| WO (1) | WO2020185606A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI760685B (zh) * | 2019-01-23 | 2022-04-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環稠合的吡唑 |
| CA3157590A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| CA3157731A1 (en) | 2019-11-21 | 2021-05-27 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as mcl-1 inhibitors |
| MX2022007474A (es) * | 2019-12-18 | 2022-08-04 | Zeno Man Inc | Compuestos macrociclicos. |
| KR20220143906A (ko) * | 2020-02-21 | 2022-10-25 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 거대환식 인돌 유도체 |
| US20230265105A1 (en) | 2020-05-29 | 2023-08-24 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| JP2023530985A (ja) | 2020-06-19 | 2023-07-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としてのｎ結合大環状７－（ピラゾール－５－イル）－インドール誘導体 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180499A (es) * | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI760685B (zh) * | 2019-01-23 | 2022-04-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環稠合的吡唑 |
-
2020
- 2020-03-06 MX MX2021010321A patent/MX2021010321A/es unknown
- 2020-03-06 EP EP20769539.6A patent/EP3924358A4/en active Pending
- 2020-03-06 BR BR112021017620A patent/BR112021017620A2/pt not_active Application Discontinuation
- 2020-03-06 CA CA3131939A patent/CA3131939A1/en active Pending
- 2020-03-06 CN CN202080028461.3A patent/CN113950481A/zh active Pending
- 2020-03-06 WO PCT/US2020/021516 patent/WO2020185606A1/en active Search and Examination
- 2020-03-06 US US17/310,824 patent/US20220144854A1/en active Pending
- 2020-03-06 AU AU2020238002A patent/AU2020238002A1/en not_active Abandoned
- 2020-03-06 SG SG11202109367WA patent/SG11202109367WA/en unknown
- 2020-03-06 KR KR1020217032295A patent/KR20210153051A/ko unknown
- 2020-03-06 JP JP2021553343A patent/JP2022524191A/ja active Pending
- 2020-03-09 TW TW109107734A patent/TW202100533A/zh unknown
-
2021
- 2021-09-02 IL IL286102A patent/IL286102A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021010321A (es) | 2021-11-17 |
| TW202100533A (zh) | 2021-01-01 |
| CA3131939A1 (en) | 2020-09-17 |
| JP2022524191A (ja) | 2022-04-28 |
| EP3924358A4 (en) | 2023-07-05 |
| AU2020238002A1 (en) | 2021-09-23 |
| WO2020185606A1 (en) | 2020-09-17 |
| US20220144854A1 (en) | 2022-05-12 |
| KR20210153051A (ko) | 2021-12-16 |
| SG11202109367WA (en) | 2021-09-29 |
| IL286102A (en) | 2021-10-31 |
| EP3924358A1 (en) | 2021-12-22 |
| CN113950481A (zh) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| BR112021012635A2 (pt) | Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2 | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| BR112022002581A2 (pt) | Inibidores heterocíclicos de rip1 quinase | |
| BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
| BR112018069612A2 (pt) | compostos de pirroltriazina como inibidores de tam | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| ECSP21091615A (es) | Derivados de benzisoxazol sulfonamida | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| BR112021018947A2 (pt) | Compostos macrocíclicos como agonistas de sting | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |